GLPwatch
Papers (10588)
Page 156 of 177, ranked by citation count.
- Acute Mesenteric Ischemia as a Severe Complication Associated With Tirzepatide: A Case Report and Safety Alert.
- Pancreatitis in Patients Receiving Tirzepatide (Mounjaro): A One-Year Audit in a UK District General Hospital.
- [Effect of byetta on renal osmoregulatory function in patients with diabetes mellitus].
- Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis.
- Beyond weight loss: multisystem benefits of obesity medications.
- Commentary on the Risks of Prescription GLP-1 Agonists in Patients on Psychiatric Medications.
- [Combination therapy with glucagon-like peptide-1 analogs and insulin: indications and contraindications in coronary artery disease patients].
- External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes.
- [Comparison of therapeutic effect of metformin hydrochloride/vildagliptin and liraglutide on type 2 diabetes mellitus in obese patients].
- [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
- PCSK9 Inhibitors in Diabetes, Tirzepatide's Cardiorenal Effects, Shingles Vaccine, and More From ACC.
- Psoriasis flare following tirzepatide initiation in a patient with plaque psoriasis in remission: A case report.
- New Drugs 2019, part 1.
- Combination of prolonged water fasting and GLP-1 for refractory morbid obesity: Case report.
- Rapid remission of Hailey-Hailey disease with tirzepatide therapy: A case report.
- GLP-1 Receptors Are Enriched in the Lymphatic Endothelium and Their Pharmacological Activation With Semaglutide Improves the Pumping Capacity of Lymphatic Vessels.
- Neuropsychiatric side effects of semaglutide in patients with dementia.
- Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
- Real-world Physical Activity and Sedentary Time Trends in Patients Undergoing Obesity Treatment: Insights From the All of Us Research Program.
- liraglutide (SAXENDA⁰) and obesit. Still no satisfactory weight loss drugs.
- Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE.
- Cardio-Obesity and Therapeutic Advances: Intersections Between Excess Adiposity, Cardiovascular Risk, and Pharmacologic Interventions.
- Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study.
- Hydrophobic ion pairing formed semaglutide designed for oral self-microemulsifying delivery in diabetes treatment.
- Semaglutide exerts anti-pulmonary fibrosis effects by inhibiting cellular senescence through activation of the Sirt1/HSF1/HSPs pathway.
- Cardiovascular and brain effects of liraglutide in transthyretin amyloidosis (ATTR) mice models.
- Oral Semaglutide: Balancing Promising Therapeutics with Adverse Effects and Access Barriers.
- Comparative analysis of IDegLira versus insulin glargine in short-term intensive therapy for overweight or obese patients with type 2 diabetes mellitus.
- A Managed Access Protocol for Liraglutide for Weight Management: A Retrospective, Observational Study in Ireland.
- Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
- Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.
- Indirect treatment comparisons: Choosing the right tool for the job.
- Sémaglutide et tirzépatide : nouvel espoir dans le traitement de l’insuffisance cardiaque ?
- GLP-1 Receptor Agonist Therapy in Older Adults with Diabetes: A Qualitative Analysis of Phase 4 ClinicalTrials.gov Studies.
- Advancing precision health discovery in a genetically diverse health system.
- Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting.
- Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review.
- Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study.
- FABP4, marker of worse prognosis in cardiovascular disease, induces neutrophil's proatherogenic phenotype which is modulated by semaglutide.
- Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity.
- [Indicators of diabetes mellitus after liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin].
- Microfluidic human liver slices reveal antifibrotic effects of liraglutide via HSC deactivation and ECM remodeling.
- Design and fabrication of a mesoporous silica scaffold for oral delivery of peptides.
- Differential effects of semaglutide and colchicine on atrial remodeling in rats with reduced ejection fraction after myocardial infarction.
- Transdermal "Natural GLP-1" Dietary Supplements Violate Law and Place Patients at Risk.
- Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.
- Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report.
- Does evidence matter? Comparative effectiveness research and prescribing of Type 2 diabetes mellitus drugs.
- Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
- [Potential of a GLP-1 receptor agonist combined with basal insulin in the treatment of type 2 diabetes].
- Ketoacidosis associated with tirzepatide use in a nonobese individual without diabetes.
- Effect of oral semaglutide on cardiometabolic risk factors in overweight and obese individuals with or without diabetes: a systematic review and meta-analysis.
- Facial nodules following filler injections after initiating compounded tirzepatide use.
- Efficacy and safety profile of Glucagon-Like Peptide-1 Receptor Agonist in obese Type-2 diabetes patients from a private institution in Karachi.
- Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.
- Perceptions and Attitudes Toward Oral Semaglutide Among Japanese Physicians and Individuals with Type 2 Diabetes: A Web-Based Survey.
- Semaglutide Modulates Visceral Adipose Tissue Lipid Metabolism in Type 2 Diabetic Mice: A Lipidomics Study.
- Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.
- Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies.
- Prioritizing Antidiabetic Drugs for Inflammatory Bowel Disease Through Inverse Signal Detection: A FAERS Pharmacovigilance Study.